CA2556213C — Contrast agents for myocardial perfusion imaging
Assigned to Lantheus Medical Imaging Inc · Expires 2013-12-17 · 12y expired
What this patent protects
The present disclosure is directed, in part, to compounds and methods for imaging mycardial perfusion, comprising administering to a patient a contrast agent such as of Formula lIl (see formula III) which comprises a compound that binds MC-1 and an imaging moiety, and scanning th…
USPTO Abstract
The present disclosure is directed, in part, to compounds and methods for imaging mycardial perfusion, comprising administering to a patient a contrast agent such as of Formula lIl (see formula III) which comprises a compound that binds MC-1 and an imaging moiety, and scanning the patient using diagnostic imaging, such as MRI, ultrasound imaging, fluorescence imaging and optical imaging.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.